Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Terminated Phase 2 Interventional Results available

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

NCT04396535
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Docetaxel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Blood Flow Restriction Therapy Following ACL Tear

NCT04374968
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear, Knee Injuries, Sport Injury
Interventions
Blood flood restriction cuff
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

NCT03310632
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Antroquinonol
Drug
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Tampa, Florida • Newnan, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00003331
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, leucovorin calcium, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Communication Bridge Speech Therapy Research Study

NCT02439853
View directory record Official record
Conditions
Primary Progressive Aphasia, Frontotemporal Dementia
Interventions
Monthly Check-in Session
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

NCT06809192
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tennessee Youth Prepared for Success

NCT06001892
View directory record Official record
Conditions
Adolescent Behavior, Adolescent Problem Behavior, Risk Reduction
Interventions
Tennessee Youth Prepared for Success
Behavioral
Lead sponsor
Centerstone Research Institute
Other
Eligibility
14 Years to 19 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

Novartis Everolimus Transition

NCT02096107
View directory record Official record
Conditions
Graft Dysfunction, Interstitial Fibrosis
Interventions
Everolimus, Standard of Care
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 22, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation

NCT06938412
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmias, Cardiac, Cardiovascular Diseases
Interventions
Physical Activity Intervention Using FitBit Wearable Device
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

NCT05878119
View directory record Official record
Conditions
Healthy
Interventions
Investigational Product - MIB 626, Placebo, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
19 Years to 40 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

NCT01767792
View directory record Official record
Conditions
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions
Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL

NCT01713439
View directory record Official record
Conditions
Neuroblastoma
Interventions
Injection of allogeneic neuroblastoma cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

NCT04740307
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Duarte, California • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 22, 2026, 10:52 AM EDT
Terminated Phase 1 Interventional

ONC201 in Pediatric H3 K27M Gliomas

NCT03416530
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 22, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

NCT06103669
View directory record Official record
Conditions
Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma, Other Cancer
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Recruiting Phase 1 Interventional

Rehabilitation Through Virtual Immersion & Integrated Exposure for Mild Traumatic Brain Injury (ReVIVE for mTBI)

NCT07890337
View directory record Official record
Conditions
Traumatic Brain Injuries, TBI (Traumatic Brain Injury), MTBI - Mild Traumatic Brain Injury, mTBI, Traumatic Brain Injury | Patient, Traumatic Brain Injury and Co-occurring Disorders, PTSD - Post Traumatic Stress Disorder
Interventions
Virtual Reality, Standard Psychotherapy
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moderate-intensity Flow-based Yoga Effects on Cognition and Stress

NCT04740229
View directory record Official record
Conditions
Stress, Psychological
Interventions
Yoga
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Bevacizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 22, 2026, 10:52 AM EDT
Completed No phase listed Observational

Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia

NCT00005619
View directory record Official record
Conditions
Leukemia
Interventions
polymerase chain reaction, flow cytometry, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 22, 2026, 10:52 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 130 Years · Female only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
14
States / cities
Casa Grande, Arizona • Fountain Valley, California • New Britain, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Health Outcomes After Locomotor Training in Spinal Cord Injury

NCT02201173
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Trauma
Interventions
Locomotor Training
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Englewood, Colorado • Louisville, Kentucky • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 22, 2026, 10:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Spectacles Lens in Concussed Kids

NCT03123822
View directory record Official record
Conditions
Concussion, Mild, Convergence Insufficiency, Accommodation; Insufficiency
Interventions
Glasses
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 22, 2026, 10:52 AM EDT
Terminated Phase 2 Interventional

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

NCT02047214
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TPI 287, Bevacizumab
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 22, 2026, 10:52 AM EDT